LUC00131I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00131I2 LUC00131I2 LU00131C LUC00131C LUC00131I2 LU C00131 I2 LUC00131 I2 LU C00131I2 LU 00131 C LU00131 C LU 00131C LU C00131 C LUC00131 C LU C00131C LU C00131 I2 LUC00131 I2 LU C00131I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607485P | 2012-03-06 | 2012-03-06 | |
| US201361759307P | 2013-01-31 | 2013-01-31 | |
| PCT/IB2013/051391 WO2013132376A1 (fr) | 2012-03-06 | 2013-02-20 | Dérivés macrocycliques pour le traitement de maladies prolifératives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LUC00131I1 LUC00131I1 (fr) | 2019-10-11 |
| LUC00131I2 true LUC00131I2 (fr) | 2020-07-16 |
Family
ID=48142828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00131C LUC00131I2 (fr) | 2012-03-06 | 2019-10-01 |
Country Status (46)
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| EP3013835B1 (fr) | 2013-06-28 | 2017-12-13 | Pfizer Inc | Formes solides d'un inhibiteur de kinases macrocycliques |
| CN104513253A (zh) | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| DK3080134T3 (en) | 2013-12-13 | 2018-10-22 | Vertex Pharma | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS |
| US9714258B2 (en) * | 2014-01-24 | 2017-07-25 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| CN103772272A (zh) * | 2014-03-04 | 2014-05-07 | 定陶县友帮化工有限公司 | 2-boc-氨基-3-羟基-5-溴吡啶的合成方法 |
| WO2016026423A1 (fr) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Macrocycles substitués utilisés comme inhibiteurs des kinases et leurs méthodes d'utilisation |
| JP6609308B2 (ja) * | 2014-08-20 | 2019-11-20 | テリジーン リミテッド | キナーゼ阻害剤としての置換マクロサイクル |
| CN107108527B (zh) | 2014-10-13 | 2022-08-02 | 阿特林制药有限责任公司 | 共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂 |
| KR102595599B1 (ko) | 2014-12-02 | 2023-11-02 | 이그니타, 인코포레이티드 | 신경모세포종의 치료를 위한 병용 |
| US11077093B2 (en) * | 2015-01-16 | 2021-08-03 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| JP6871903B2 (ja) * | 2015-07-02 | 2021-05-19 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子 |
| EP3319969B1 (fr) | 2015-07-06 | 2024-04-03 | Turning Point Therapeutics, Inc. | Polymorphe de macrocycle diarylique |
| EP3325488B1 (fr) | 2015-07-21 | 2020-06-24 | Turning Point Therapeutics, Inc. | Macrocycle diaryle chiral et son utilisation dans le traitement du cancer |
| SI3328867T1 (sl) * | 2015-07-31 | 2021-04-30 | Pfizer Inc. | Kristalna oblika proste baze lorlatiniba |
| US20180282415A1 (en) | 2015-09-30 | 2018-10-04 | Merck Patent Gmbh | Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer |
| KR20180096621A (ko) | 2015-12-18 | 2018-08-29 | 이그니타, 인코포레이티드 | 암의 치료용 조합물 |
| ES2812336T3 (es) * | 2016-03-03 | 2021-03-16 | Shenzhen Targetrx Inc | Macrocíclico y composición que comprende el mismo |
| CN105732355A (zh) * | 2016-04-07 | 2016-07-06 | 戊言医药科技（上海）有限公司 | 1-(5-氟-2-碘苯基)乙酮的制备方法 |
| CN105646355A (zh) * | 2016-04-07 | 2016-06-08 | 戊言医药科技（上海）有限公司 | 3-(羟甲基)-1-甲基-吡唑-5-甲腈的制备方法 |
| US11078215B2 (en) | 2016-04-08 | 2021-08-03 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| WO2017180723A1 (fr) * | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Inhibiteurs de l'atr (ataxia telangiectasia and rad3 related) et leurs méthodes d'utilisation |
| CN105801603B (zh) * | 2016-04-13 | 2018-10-02 | 成都倍特药业有限公司 | 一种具有大环结构的alk抑制剂及其制备方法 |
| AU2017302019A1 (en) | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| WO2018137679A1 (fr) * | 2017-01-25 | 2018-08-02 | Teligene Ltd | Procédé de préparation de (10r) -7- (2-aminoacétyl) amino-12-fluoro-2, 10, 16-triméthyl-15-oxo-10, 15, 16, 17-tétrahydro-2h-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotétradécine-3-carbonitrile |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CA3063901A1 (fr) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Amides de pyridone deuteres et leurs promedicaments utilises en tant que modulateurs de canaux sodiques |
| MX2019015895A (es) | 2017-06-30 | 2020-02-07 | Bayer Animal Health Gmbh | Nuevos derivados de azaquinolina. |
| IL271759B2 (en) | 2017-07-19 | 2024-01-01 | Ignyta Inc | Pharmaceutical preparations that include anthraxtinib |
| UA126158C2 (uk) | 2017-07-28 | 2022-08-25 | Тьорнінґ Поінт Терапьютикс, Інк. | Макроциклічні сполуки і їх використання |
| ES2952985T3 (es) * | 2017-10-10 | 2023-11-07 | Pfizer | Forma cristalina de hidrato de base libre de lorlatinib |
| JP7311498B2 (ja) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| PL3728271T3 (pl) | 2017-12-19 | 2023-01-23 | Turning Point Therapeutics, Inc. | Związki makrocykliczne do leczenia chorób |
| CN111918650A (zh) | 2018-02-12 | 2020-11-10 | 沃泰克斯药物股份有限公司 | 治疗疼痛的方法 |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| EP3784675A1 (fr) | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Formes à l'état solide de lorlatinib et préparation associée |
| CN111918868B (zh) * | 2018-05-04 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
| CN108621206B (zh) * | 2018-05-07 | 2020-08-14 | 昆山国显光电有限公司 | 手套箱系统以及手套箱系统的保养方法 |
| CN112703001A (zh) * | 2018-09-18 | 2021-04-23 | 株式会社益力多本社 | 使用喹啉羧酰胺衍生物的癌症联用疗法 |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| CN109081810A (zh) * | 2018-09-20 | 2018-12-25 | 沈阳药科大学 | 1-甲基-3–((甲氨基)甲基)-1h-吡唑-5-腈的合成方法 |
| CN111233833A (zh) * | 2018-11-28 | 2020-06-05 | 深圳市塔吉瑞生物医药有限公司 | 一种氘代大环化合物的制备方法 |
| BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
| CN109651418A (zh) * | 2019-01-25 | 2019-04-19 | 安庆多辉生物科技有限公司 | 一种劳拉替尼原料药合成中间体及有机金属钯催化偶联制备劳拉替尼的方法 |
| CN109651397A (zh) * | 2019-01-25 | 2019-04-19 | 安庆多辉生物科技有限公司 | 一种劳拉替尼中间体及制备劳拉替尼的方法 |
| CN109651398B (zh) * | 2019-01-25 | 2021-07-30 | 安庆多辉生物科技有限公司 | 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法 |
| CN111499514A (zh) * | 2019-01-31 | 2020-08-07 | 连云港润众制药有限公司 | 一种罗沙司他中间体的制备方法 |
| EP3941457A4 (fr) * | 2019-03-21 | 2023-04-26 | Merck Sharp & Dohme LLC | Inhibiteurs d'histone désacétylase utiles pour le traitement ou la prévention d'une infection par le vih |
| CN112533927A (zh) * | 2019-05-14 | 2021-03-19 | 苏州韬略生物科技有限公司 | 可用作激酶抑制剂的被取代的大环 |
| WO2021011345A1 (fr) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Lorlatinib cristallin : acide fumarique et formes à l'état solide correspondantes |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| EP4041396A1 (fr) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorphe de lorlatinib |
| CN112812128B (zh) * | 2019-11-18 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 作为alk和ros调节剂的大环化合物 |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Transduced tetrahydrofurans as sodium channel modulators |
| CN111170908B (zh) * | 2020-01-09 | 2021-08-17 | 北京印刷学院 | 一种2，4-二甲基-3-甲磺酰基卤苯的合成方法 |
| WO2021176349A1 (fr) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combinaison d'un inhibiteur de kinase du lymphome anaplasique et d'un inhibiteur de kinase dépendant de la cycline |
| JP2023525040A (ja) | 2020-05-05 | 2023-06-14 | ヌバレント， インク． | ヘテロ芳香族大環状エーテル化学療法剤 |
| CN115916754A (zh) | 2020-05-05 | 2023-04-04 | 纽威伦特公司 | 杂芳族大环醚化学治疗剂 |
| WO2021233296A1 (fr) * | 2020-05-18 | 2021-11-25 | 深圳市塔吉瑞生物医药有限公司 | Forme solide de composé macrocyclique, sa préparation et son utilisation |
| CN116171279A (zh) * | 2020-07-10 | 2023-05-26 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| CA3202770A1 (fr) * | 2020-12-17 | 2022-06-23 | Blossomhill Therapeutics, Inc. | Macrocycles et leur utilisation |
| CN114805371A (zh) * | 2021-01-19 | 2022-07-29 | 江苏开元药业有限公司 | 含2-氨基嘧啶大环类化合物及其制备方法和用途 |
| WO2022182845A1 (fr) * | 2021-02-25 | 2022-09-01 | Blossomhill Therapeutics, Inc. | Macrocycles et leur utilisation |
| EP4320153A1 (fr) | 2021-04-09 | 2024-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de traitement d'un lymphome anaplasique à grandes cellules |
| CN115246843A (zh) * | 2021-04-26 | 2022-10-28 | 苏州东南药业股份有限公司 | 一类十四元稠环衍生物及其应用 |
| EP4347031A1 (fr) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques |
| TW202320768A (zh) * | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| WO2023156983A1 (fr) | 2022-02-21 | 2023-08-24 | Universidade Nova De Lisboa | Composés et compositions contre des maladies neurodégénératives |
| EP4230201A1 (fr) | 2022-02-21 | 2023-08-23 | Universidade Nova De Lisboa | Composition pour le traitement de maladies neurodégénératives |
| CN115746023A (zh) * | 2022-10-27 | 2023-03-07 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| JO2785B1 (en) * | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| WO2006000020A1 (fr) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Lixiviation amelioree de metaux de base |
| CA2578370A1 (fr) | 2004-08-25 | 2006-03-02 | Pfizer Inc. | Triazolobenzodiazepines et leur utilisation en tant qu'antagonistes de la vasopressine |
| ATE463486T1 (de) | 2004-08-26 | 2010-04-15 | Pfizer | Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer |
| CN101018780B (zh) | 2004-08-26 | 2012-01-11 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物 |
| EP1710246A1 (fr) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Macrocycles de sulfoximine-pyrmidine et leurs sels correspondants, leurs procédé de fabrication, et leurs utilisation pharmaceutique contre le cancer |
| AU2006323025B2 (en) | 2005-12-05 | 2012-07-05 | Pfizer Products Inc. | Polymorphs of a c-Met/HGFR inhibitor |
| EP1959955B1 (fr) | 2005-12-05 | 2010-11-17 | Pfizer Products Inc. | Méthode de traitement d'une croissance cellulaire anormale |
| WO2008088881A1 (fr) | 2007-01-19 | 2008-07-24 | Xcovery, Inc. | Composés inhibiteurs de kinase |
| WO2008105526A1 (fr) | 2007-03-01 | 2008-09-04 | Chugai Seiyaku Kabushiki Kaisha | Composé macrocyclique |
| JP4468487B1 (ja) * | 2007-03-13 | 2010-05-26 | ファイザー・プロダクツ・インク | エリスロマイシンをベースとするマクロライド |
| EP2265270A1 (fr) * | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | Inhibiteurs de 2-aminopyridine kinases |
| CA2722326A1 (fr) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Composes macrocycliques et leur utilisation a titre d'inhibiteurs de kinase |
| ES2494390T3 (es) * | 2008-06-06 | 2014-09-15 | Sanofi | Derivados macrocíclicos de urea y de sulfamida como inhibidores de TAFIa |
| CN102143750B (zh) * | 2008-09-08 | 2014-04-02 | 默克专利有限公司 | 用作蛋白激酶抑制剂的大环嘧啶 |
| WO2010085597A1 (fr) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Composés macrocycliques et leur utilisation en tant qu'inhibiteurs des kinases |
| EP2490766A1 (fr) | 2009-10-21 | 2012-08-29 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composés amides macrocycliques non naturels inhibiteurs de hdac6 et leurs utilisations en tant qu'agents thérapeutiques |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| WO2011138751A2 (fr) * | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Dérivés hétérocycliques destinés au traitement de maladies |
| MX365251B (es) * | 2010-05-20 | 2019-05-28 | Array Biopharma Inc | Compuestos macrocíclicos como inhibidores de trk cinasa. |
| US8975232B2 (en) | 2010-07-29 | 2015-03-10 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
| WO2012125603A1 (fr) | 2011-03-16 | 2012-09-20 | Cephalon, Inc. | Composés macrocylciques comme inhibiteurs d'alk, de fak et de jak2 |
-
2013
- 2013-02-20 ES ES13717555.0T patent/ES2621220T3/es active Active
- 2013-02-20 SI SI201330542A patent/SI2822953T1/sl unknown
- 2013-02-20 DK DK13717555.0T patent/DK2822953T5/en active
- 2013-02-20 MY MYPI2014702342A patent/MY169142A/en unknown
- 2013-02-20 NZ NZ627900A patent/NZ627900A/en unknown
- 2013-02-20 SG SG11201404451TA patent/SG11201404451TA/en unknown
- 2013-02-20 HU HUE13717555A patent/HUE034118T2/en unknown
- 2013-02-20 CN CN201380012703.XA patent/CN104169286B/zh active Active
- 2013-02-20 JP JP2014560470A patent/JP5823066B2/ja active Active
- 2013-02-20 MX MX2014010716A patent/MX350844B/es active IP Right Grant
- 2013-02-20 MD MDA20140086A patent/MD4590C1/ro active IP Right Grant
- 2013-02-20 AP AP2014007881A patent/AP2014007881A0/xx unknown
- 2013-02-20 EA EA201491394A patent/EA026155B9/ru active Protection Beyond IP Right Term
- 2013-02-20 CA CA2863892A patent/CA2863892C/fr active Active
- 2013-02-20 PT PT137175550T patent/PT2822953T/pt unknown
- 2013-02-20 PE PE2014001329A patent/PE20142339A1/es active IP Right Grant
- 2013-02-20 EP EP13717555.0A patent/EP2822953B9/fr active Active
- 2013-02-20 BR BR112014022106-5A patent/BR112014022106B1/pt active IP Right Grant
- 2013-02-20 PL PL13717555T patent/PL2822953T3/pl unknown
- 2013-02-20 AU AU2013229173A patent/AU2013229173B2/en active Active
- 2013-02-20 RS RS20170280A patent/RS55814B1/sr unknown
- 2013-02-20 WO PCT/IB2013/051391 patent/WO2013132376A1/fr active Application Filing
- 2013-02-20 LT LTEP13717555.0T patent/LT2822953T/lt unknown
- 2013-02-20 GE GEAP201313564A patent/GEP201606560B/en unknown
- 2013-02-20 KR KR1020147027905A patent/KR101692600B1/ko active IP Right Grant
- 2013-02-20 ME MEP-2017-42A patent/ME02630B/fr unknown
- 2013-03-04 AR ARP130100694 patent/AR090230A1/es active IP Right Grant
- 2013-03-04 TW TW102107486A patent/TWI476199B/zh active
- 2013-03-05 US US13/786,106 patent/US8680111B2/en active Active
- 2013-03-06 UY UY34657A patent/UY34657A/es active IP Right Grant
-
2014
- 2014-01-15 US US14/156,144 patent/US9133215B2/en active Active
- 2014-08-01 CR CR20140370A patent/CR20140370A/es unknown
- 2014-08-06 CL CL2014002084A patent/CL2014002084A1/es unknown
- 2014-08-11 IL IL234062A patent/IL234062A/en active IP Right Grant
- 2014-08-18 DO DO2014000188A patent/DOP2014000188A/es unknown
- 2014-08-25 ZA ZA2014/06244A patent/ZA201406244B/en unknown
- 2014-09-05 PH PH12014501992A patent/PH12014501992A1/en unknown
- 2014-09-05 NI NI201400102A patent/NI201400102A/es unknown
- 2014-09-05 GT GT201400187A patent/GT201400187A/es unknown
- 2014-09-08 CO CO14198153A patent/CO7061081A2/es unknown
- 2014-12-19 HK HK14112733.1A patent/HK1199247A1/zh unknown
-
2015
- 2015-10-05 JP JP2015197955A patent/JP6002825B2/ja active Active
-
2017
- 2017-02-22 HR HRP20170287TT patent/HRP20170287T2/hr unknown
- 2017-03-27 CY CY20171100376T patent/CY1118771T1/el unknown
-
2019
- 2019-08-02 CY CY2019033C patent/CY2019033I2/el unknown
- 2019-08-19 NO NO2019034C patent/NO2019034I1/no unknown
- 2019-09-12 HU HUS1900040C patent/HUS1900040I1/hu unknown
- 2019-09-17 NL NL301006C patent/NL301006I2/nl unknown
- 2019-10-01 LU LU00131C patent/LUC00131I2/fr unknown
- 2019-10-18 LT LTPA2019519C patent/LTC2822953I2/lt unknown
- 2019-10-23 FR FR19C1062C patent/FR19C1062I2/fr active Active